Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis
Accesswire
*STOCKHOLM, SWEDEN / ACCESSWIRE / May 20, 2024 /* Vicore Pharma Holding (STO:VICO)
· Buloxibutid improved lung..